EUVIMEDEUVIMED entdecken
Open Access

Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs

Davide Provasi iD, Marta Filizola iD

Biochemistry · 18.03.2025 · 64 (6) · 1328-1337

DOI: 10.1021/acs.biochem.4c00832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry, online erschienen am 08.03.2025. Verfasst von Davide Provasi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Deep Learning. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

G protein-coupled receptors (GPCRs) remain a focal point of research due to their critical roles in cell signaling and their prominence as drug targets. However, directly linking drug efficacy to the receptor-mediated activation of specific intracellular transducers and the resulting physiological outcomes remains challenging. It is unclear whether the enhanced therapeutic window of certain drugs─defined as the dose range that provides effective therapy with minimal side effects─stems from their low intrinsic efficacy across all signaling pathways or ligand bias, wherein specific transducer subtypes are preferentially activated in a given cellular system compared to a reference ligand. Accurately predicting safer compounds, through either low intrinsic efficacy or ligand bias, would greatly advance drug development. While AI models hold promise for such predictions, the development of deep learning models capable of reliably forecasting GPCR ligands with defined bioactivities remains challenging, largely due to the limited availability of high-quality data. To address this, we pretrained a model on receptor sequences and ligand data sets across all class A GPCRs and then refined it to predict low-efficacy compounds or biased agonists for individual class A GPCRs. This was achieved using transfer learning and a neural network incorporating natural language processing of target sequences and receptor mutation effects on signaling. These two fine-tuned models─one for low-efficacy agonists and one for biased agonists─are available on demand for each class A GPCR and enable virtual screening of large chemical libraries, thereby facilitating the discovery of compounds with potentially improved safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledDeep LearningHumansLigandsDrug Evaluation, PreclinicalSignal Transduction

Substanzen

Receptors, G-Protein-CoupledLigands

Autor:innen und Institutionen

  • Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

ORCID-Profile: Davide Provasi, Marta Filizola

Förderung

  • NIDA NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Provasi, D., & Filizola, M. (2025). Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs. Biochemistry, 64(6), 1328-1337. https://doi.org/10.1021/acs.biochem.4c00832

Vancouver

Provasi D, Filizola M. Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs. Biochemistry. 2025;64(6):1328-1337. doi:10.1021/acs.biochem.4c00832

BibTeX
@article{Provasi2025,
  author = {Provasi, Davide and Filizola, Marta},
  title = {Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs},
  journal = {Biochemistry},
  year = {2025},
  volume = {64},
  number = {6},
  pages = {1328--1337},
  doi = {10.1021/acs.biochem.4c00832}
}
Kostenlos starten →